Scholar Rock Holding Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report; quarterly results are not clearly provided in the filing text. Scholar Rock is a clinical-stage biopharmaceutical company with no product sales.
Business context and pipeline
The company develops antibodies intended to selectively inhibit activation of latent growth factors. Its lead programs were apitegromab for spinal muscular atrophy (SMA) and SRK-181 for cancers resistant to anti-PD-(L)1 therapies. It also had fibrosis and other early-stage research programs.
- Apitegromab: The company reported positive 12-month topline results from its Phase 2 TOPAZ trial. Its pivotal Phase 3 SAPPHIRE trial began in January 2022, after year-end, in non-ambulatory Type 2 and Type 3 SMA patients receiving background SMN therapy.
- SRK-181: The Phase 1 DRAGON trial was ongoing; dose-expansion cohorts began in 2021. Initial clinical data from dose escalation were presented in November 2021. The company anticipated initial expansion-cohort safety and efficacy data in 2022.
- The three-year Gilead fibrosis collaboration ended in December 2021. In January 2022, Gilead’s option period was terminated, returning rights to the relevant antibody programs to Scholar Rock.
Financial performance and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $18.8 million | $15.4 million | +22.2% |
| Research and development expense | $108.5 million | $74.1 million | +46.5% |
| General and administrative expense | $40.3 million | $28.2 million | +42.7% |
| Total operating expenses | $148.7 million | $102.3 million | +45.4% |
| Operating loss | $129.9 million | $86.9 million | Loss widened |
| Net loss | $131.8 million | $86.5 million | Loss widened 52.4% |
| Net loss per share, basic and diluted | $3.59 | $2.81 | Loss per share increased |
Revenue was entirely collaboration-related, principally from Gilead; there were no product sales. The reported loss reflects the company’s development-stage operations, so a product gross margin is not applicable. Revenue growth was outweighed by higher operating expenses, primarily increased apitegromab development costs, staffing, facilities and equity compensation.
- Cash and investments: $253.0 million at December 31, 2021, versus $341.0 million a year earlier. Management estimated these resources would fund operating expenses and capital needs into mid-2023, based on its then-current plan; it also stated additional capital would be needed to complete clinical development of current programs.
- Cash flows: Operating activities used $126.8 million, compared with $60.3 million in 2020. Investing activities provided $134.3 million, principally reflecting marketable-security maturities and purchases. Financing activities provided $45.0 million. Cash, cash equivalents and restricted cash increased $52.5 million, while cash plus marketable securities declined approximately $88 million.
- Debt: The company drew the second $25 million tranche of its loan facility in December 2021, bringing original principal drawn to $50 million. Debt had a May 2025 maturity; principal payments were scheduled to begin in December 2022. The stated interest rate was the greater of prime plus 4.60% or 7.85%, with a 4% final payment fee.
- Balance sheet: Total assets were $304.4 million, total liabilities $132.4 million and stockholders’ equity $172.1 million at year-end. Current liabilities included $33.2 million of deferred revenue related to Gilead option material rights, expected to be recognized in Q1 2022 following termination of the options.
Material changes, outlook and risks
- R&D spending rose substantially as apitegromab advanced toward Phase 3 and the company expanded internal capabilities. G&A also increased with headcount, equity compensation, professional fees and new facilities.
- The company had incurred losses in every year since inception and expected significant losses and expenses to continue. It provided no product-revenue guidance.
- COVID-19 disrupted trial-site access, dosing and enrollment. Four TOPAZ participants missed three doses each during the 12-month treatment period because of site-access restrictions; the company also reported slower-than-projected DRAGON enrollment. Supply-chain and third-party manufacturing risks remained, including reliance on a single drug-substance supplier for both clinical candidates.
- Key uncertainties include whether early-stage and Phase 2 results will translate into pivotal-trial success, trial enrollment and execution, safety and regulatory approval, manufacturing capacity, future financing needs, reimbursement and competition. Two European patents were subject to opposition proceedings. The company reported no material legal proceedings.
- The Gilead option termination ended a potential route for partner-led advancement of those programs; the returned fibrosis assets remained preclinical. The filing does not provide a clear quantitative forecast of future expenses, cash burn or financing proceeds beyond management’s runway estimate.
Important facts for investors to verify
- Subsequent SAPPHIRE enrollment, interim-analysis timing and results, including the effects of background SMN therapies and any trial disruptions.
- DRAGON dose-expansion enrollment, safety, tumor-response data and timing of reported results; distinguish preliminary investigator assessments from final or centrally reviewed results.
- Cash burn against the mid-2023 runway estimate, financing plans, ATM usage and loan repayment schedule.
- Recognition of the $33.2 million Gilead-related deferred revenue in Q1 2022, and the development plans and funding for returned fibrosis assets.
- Clinical-supply continuity, reliance on third-party manufacturers, and outcomes of the European patent opposition proceedings.